ZFIN ID: ZDB-FISH-220811-14
Fish name: chodlue105/ue105; ml2Tg
Genotype: chodlue105/ue105; ml2Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by chodlue105/ue105; ml2Tg
No data available
GENE EXPRESSION
Gene expression in chodlue105/ue105; ml2Tg
RNA expression No data available
Reporter gene expression
Expressed Gene Structure Conditions Figures
GFP control Fig. 2. with imageFig. 3. with imageFig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
chemical treatment by environment: dipyridamole Fig. 2. with imageFig. 3. with imageFig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
PHENOTYPE
Phenotype in chodlue105/ue105; ml2Tg
Phenotype Conditions Figures
CaP motoneuron axon decreased length, abnormal control Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon decreased length, abnormal chemical treatment by environment: indometacin Fig. 2. with image from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated chemical treatment by environment: dipyridamole Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Fig. 2. with image from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension decreased process quality, abnormal chemical treatment by environment: indometacin Fig. 2. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension decreased process quality, abnormal control Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated chemical treatment by environment: dipyridamole Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Fig. 2. with imageFig. 3. with image from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Fig. 2. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse znp-1 labeling amount, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 5. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse area, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 5. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse area, ameliorated chemical treatment by environment: dipyridamole Fig. 4. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse znp-1 labeling increased amount, abnormal control Fig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse increased area, abnormal control Fig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
CaP motoneuron presynapse assembly decreased process quality, abnormal control Fig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated chemical treatment by environment: dipyridamole Fig. 4. with image from Oprişoreanu et al., 2021
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 5. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction area, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 5. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction area, ameliorated chemical treatment by environment: dipyridamole Fig. 4. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction increased area, abnormal control Fig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development decreased process quality, abnormal control Fig. 4. with imageFig. 5. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development process quality, ameliorated chemical treatment by environment: dipyridamole Fig. 4. with image from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development process quality, ameliorated chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid Fig. 5. with image from Oprişoreanu et al., 2021

CITATIONS  (1)